These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 39288118)

  • 1. Identification of antibody targets associated with lower HIV viral load and viremic control.
    Grant-McAuley W; Morgenlander WR; Ruczinski I; Kammers K; Laeyendecker O; Hudelson SE; Thakar M; Piwowar-Manning E; Clarke W; Breaud A; Ayles H; Bock P; Moore A; Kosloff B; Shanaube K; Meehan SA; van Deventer A; Fidler S; Hayes R; Larman HB; Eshleman SH;
    PLoS One; 2024; 19(9):e0305976. PubMed ID: 39288118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive profiling of pre-infection antibodies identifies HIV targets associated with viremic control and viral load.
    Grant-McAuley W; Morgenlander W; Hudelson SE; Thakar M; Piwowar-Manning E; Clarke W; Breaud A; Blankson J; Wilson E; Ayles H; Bock P; Moore A; Kosloff B; Shanaube K; Meehan SA; van Deventer A; Fidler S; Hayes R; Ruczinski I; Kammers K; Laeyendecker O; Larman HB; Eshleman SH
    Front Immunol; 2023; 14():1178520. PubMed ID: 37744365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression.
    Kammers K; Chen A; Monaco DR; Hudelson SE; Grant-McAuley W; Moore RD; Alter G; Deeks SG; Morrison CS; Eller LA; Blankson JN; Laeyendecker O; Ruczinski I; Eshleman SH; Larman HB
    Front Immunol; 2021; 12():740395. PubMed ID: 34512672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-level analysis of natural control of HIV infection in Zambia and South Africa: HPTN 071 (PopART).
    Grant-McAuley W; Piwowar-Manning E; Clarke W; Breaud A; Zewdie KB; Moore A; Ayles HM; Kosloff B; Shanaube K; Bock P; Meehan SA; Maarman G; Fidler S; Hayes R; Donnell D; Eshleman SH;
    J Int AIDS Soc; 2023 Oct; 26(10):e26179. PubMed ID: 37886843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.
    Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.
    Ferre AL; Lemongello D; Hunt PW; Morris MM; Garcia JC; Pollard RB; Yee HF; Martin JN; Deeks SG; Shacklett BL
    J Virol; 2010 Oct; 84(19):10354-65. PubMed ID: 20668079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy.
    Omondi FH; Sudderuddin H; Shahid A; Kinloch NN; Jones BR; Miller RL; Tsai O; MacMillan D; Trocha A; Brockman MA; Brumme CJ; Joy JB; Liang R; Walker BD; Brumme ZL
    mBio; 2021 Dec; 12(6):e0249021. PubMed ID: 34781741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural control of HIV infection in young women in South Africa: HPTN 068.
    Sivay MV; Fogel JM; Wang J; Zhang Y; Piwowar-Manning E; Clarke W; Breaud A; Blankson J; Hamilton EL; Kahn K; Selin A; Gomez-Olive FX; MacPhail C; Hughes JP; Pettifor A; Eshleman SH
    HIV Clin Trials; 2018 Oct; 19(5):202-208. PubMed ID: 30522410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers.
    de Mulder M; SenGupta D; Deeks SG; Martin JN; Pilcher CD; Hecht FM; Sacha JB; Nixon DF; Michaud HA
    Retrovirology; 2017 Aug; 14(1):41. PubMed ID: 28830571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.
    Johansson SE; Rollman E; Chung AW; Center RJ; Hejdeman B; Stratov I; Hinkula J; Wahren B; Kärre K; Kent SJ; Berg L
    Viral Immunol; 2011 Oct; 24(5):359-68. PubMed ID: 21958370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing analyses of the emergence and maintenance of mutations in CTL epitopes in HIV controllers with differential viremia control.
    Caetano DG; Côrtes FH; Bello G; Teixeira SLM; Hoagland B; Grinsztejn B; Veloso VG; Guimarães ML; Morgado MG
    Retrovirology; 2018 Sep; 15(1):62. PubMed ID: 30201008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.
    Tomescu C; Liu Q; Ross BN; Yin X; Lynn K; Mounzer KC; Kostman JR; Montaner LJ
    PLoS One; 2014; 9(7):e103209. PubMed ID: 25078947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyfunctional Fc Dependent Activity of Antibodies to Native Trimeric Envelope in HIV Elite Controllers.
    Kant S; Zhang N; Barbé A; Routy JP; Tremblay C; Thomas R; Szabo J; Côté P; Trottier B; LeBlanc R; Rouleau D; Harris M; Dupuy FP; Bernard NF
    Front Immunol; 2020; 11():583820. PubMed ID: 33101312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of population-level HIV-1 incidence estimation by cross-sectional incidence assays in the HPTN 071 (PopART) trial.
    Klock E; Wilson E; Fernandez RE; Piwowar-Manning E; Moore A; Kosloff B; Bwalya J; Bell-Mandla N; James A; Ayles H; Bock P; Donnell D; Fidler S; Hayes R; Eshleman SH; Laeyendecker O;
    J Int AIDS Soc; 2021 Dec; 24(12):e25830. PubMed ID: 34897992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers.
    Gonzalo-Gil E; Ikediobi U; Sutton RE
    Yale J Biol Med; 2017 Jun; 90(2):245-259. PubMed ID: 28656011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design.
    Madhavi V; Wren LH; Center RJ; Gonelli C; Winnall WR; Parsons MS; Kramski M; Kent SJ; Stratov I
    AIDS; 2014 Aug; 28(13):1859-70. PubMed ID: 24937308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.
    Pereyra F; Addo MM; Kaufmann DE; Liu Y; Miura T; Rathod A; Baker B; Trocha A; Rosenberg R; Mackey E; Ueda P; Lu Z; Cohen D; Wrin T; Petropoulos CJ; Rosenberg ES; Walker BD
    J Infect Dis; 2008 Feb; 197(4):563-71. PubMed ID: 18275276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses.
    Salgado M; Garcia-Minambres A; Dalmau J; Jiménez-Moyano E; Viciana P; Alejos B; Clotet B; Prado JG; Martinez-Picado J
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function.
    Curriu M; Fausther-Bovendo H; Pernas M; Massanella M; Carrillo J; Cabrera C; López-Galíndez C; Clotet B; Debré P; Vieillard V; Blanco J
    PLoS One; 2012; 7(2):e30330. PubMed ID: 22312424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.